Company

Processa Pharmaceuticals, Inc.

Headquarters: Hanover, MD, United States

Employees: 14

CEO: Dr. David Young Ph.D., Pharm.D.

NASDAQ: PCSA -2.00%

Market Cap

$7.8 Million

USD as of Jan. 1, 2024

Market Cap History

Processa Pharmaceuticals, Inc. market capitalization over time

Evolution of Processa Pharmaceuticals, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Processa Pharmaceuticals, Inc.

Detailed Description

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of gastroparesis; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It has a license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was incorporated in 2011 and is based in Hanover, Maryland.

Top 1-year algo backtest: +269.94%

$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Processa Pharmaceuticals, Inc. has the following listings and related stock indices.


Stock: NASDAQ: PCSA wb_incandescent

Stock: OTC: PCSA wb_incandescent

Details

Headquarters:

7380 Coca Cola Drive

Suite 106

Hanover, MD 21076

United States

Phone: 443 776 3133

Fax: 443 288 4420